Hyperoside is also highly acclaimed in the realm of cancer therapy (Peng et al., 2023), as it has been demonstrated to effectively impede the growth of cervical cancer cells by targeting the V-Myc myelocytomatosis viral oncogene homolog (C-MYC) gene (Guo W. et al., 2019). This evidence concerns the gene MYC and cervical carcinoma.